Several studies reported that inhibition of CARMA3 decreased cell proliferation, migration, and tumor growth in NSCLC, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, and colorectal cancer [4,5,6,7,8]. Here, CARD10 is linked to neoplasm.